DE60219142D1 - Verfahren zum erhöhen der zuführung einer therapeutischen nukleinsäure - Google Patents

Verfahren zum erhöhen der zuführung einer therapeutischen nukleinsäure

Info

Publication number
DE60219142D1
DE60219142D1 DE60219142T DE60219142T DE60219142D1 DE 60219142 D1 DE60219142 D1 DE 60219142D1 DE 60219142 T DE60219142 T DE 60219142T DE 60219142 T DE60219142 T DE 60219142T DE 60219142 D1 DE60219142 D1 DE 60219142D1
Authority
DE
Germany
Prior art keywords
nucleic acid
increasing
introduction
therapeutic nucleic
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60219142T
Other languages
English (en)
Other versions
DE60219142T2 (de
Inventor
James G Barsoum
Michael Parr
Stephen E Fawell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of DE60219142D1 publication Critical patent/DE60219142D1/de
Application granted granted Critical
Publication of DE60219142T2 publication Critical patent/DE60219142T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DE60219142T 2001-01-22 2002-01-22 Verfahren zum erhöhen der zuführung einer therapeutischen nukleinsäure Expired - Fee Related DE60219142T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26341601P 2001-01-22 2001-01-22
US263416P 2001-01-22
PCT/US2002/001797 WO2002056918A2 (en) 2001-01-22 2002-01-22 Method of enhancing delivery of a therapeutic nucleic acid

Publications (2)

Publication Number Publication Date
DE60219142D1 true DE60219142D1 (de) 2007-05-10
DE60219142T2 DE60219142T2 (de) 2007-12-13

Family

ID=23001688

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60219142T Expired - Fee Related DE60219142T2 (de) 2001-01-22 2002-01-22 Verfahren zum erhöhen der zuführung einer therapeutischen nukleinsäure

Country Status (13)

Country Link
US (1) US7534424B2 (de)
EP (1) EP1363676B1 (de)
JP (1) JP2005502585A (de)
AT (1) ATE357935T1 (de)
AU (1) AU2002237910B2 (de)
CA (1) CA2435443A1 (de)
CY (1) CY1106676T1 (de)
DE (1) DE60219142T2 (de)
DK (1) DK1363676T3 (de)
ES (1) ES2283524T3 (de)
NZ (1) NZ527645A (de)
PT (1) PT1363676E (de)
WO (1) WO2002056918A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
JP4736413B2 (ja) * 2004-12-14 2011-07-27 富士ゼロックス株式会社 生体分子保持物及び生体分子の保存方法
WO2011074564A1 (ja) * 2009-12-15 2011-06-23 タカラバイオ株式会社 アデノウイルスベクターの製造方法
US20140141065A1 (en) * 2012-11-19 2014-05-22 Discovery Genomics, Inc. Method to achieve extended expression of dna infused into liver

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE19525900C1 (de) * 1995-07-15 1996-12-12 Max Planck Gesellschaft Leberspezifischer Adenovirus-Expressionsvektor
AU740428B2 (en) * 1997-08-29 2001-11-01 Biogen Idec Ma Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US6696423B1 (en) * 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
WO2001060377A2 (en) * 2000-02-17 2001-08-23 Genzyme Corporation Methods for treatment of lysosomal storage diseases using biphosphonates

Also Published As

Publication number Publication date
CY1106676T1 (el) 2012-05-23
NZ527645A (en) 2008-10-31
EP1363676B1 (de) 2007-03-28
US7534424B2 (en) 2009-05-19
CA2435443A1 (en) 2002-07-25
JP2005502585A (ja) 2005-01-27
AU2002237910C1 (en) 2002-07-30
WO2002056918B1 (en) 2004-04-08
EP1363676A2 (de) 2003-11-26
ES2283524T3 (es) 2007-11-01
DE60219142T2 (de) 2007-12-13
WO2002056918A3 (en) 2002-11-14
US20040086486A1 (en) 2004-05-06
DK1363676T3 (da) 2007-07-23
AU2002237910B2 (en) 2007-01-25
WO2002056918A2 (en) 2002-07-25
PT1363676E (pt) 2007-06-22
ATE357935T1 (de) 2007-04-15

Similar Documents

Publication Publication Date Title
WO2002006316A3 (en) Alpha-msh related compounds and methods of use
ZA200906125B (en) Xylanases nucleic acids encoding them and methods for making and using them
ATE376434T1 (de) Injektionsgerät für mrna applikation
GB2398220A (en) Automated foot bath apparatus and method
RS53988B1 (en) IDENTIFICATION OF TUMOR RELATED ANTIGENS FOR DIAGNOSTICS AND THERAPY
DK0981630T3 (da) Polypeptider med prolyldipeptidylaminopeptidaseaktivitet og nukleinsyrer, der koder for samme
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
WO2003093469A3 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
TW200608993A (en) Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
ES2534303T3 (es) Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
LU91680I2 (fr) "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)"
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
NO20062080L (no) Nukleinsyrekonstrukter
ATE511655T1 (de) Verfahren zur auswertung eines myelounterdrückungszustands
ATE551404T1 (de) Verfahren zur verbesserung der lagerstabilität von kompositpartikel-dispersionen
DE602004029699D1 (de) Nukleinsäuren zum auslösen der tumorzellsterblichkeit
EP1339875A4 (de) Zusammensetzungen und verfahren zur schnellen erzeugung rekombinanter nukleinsäuremoleküle
WO2004046494A3 (en) Method using particulate chelates to stimulate production of petroleum in carbonate formations
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
WO2006020949A3 (en) Combined gene therapy for the treatment of macroscopic gliomas
ATE471371T1 (de) Antikrebsmittel mit verotoxinvarianten
DE60330387D1 (de) Spielzeugbahn und verfahren zu ihrem auf- und abbau
DE60219142D1 (de) Verfahren zum erhöhen der zuführung einer therapeutischen nukleinsäure
ATE371031T1 (de) Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee